{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:10Z","timestamp":1791920890449,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12185-019-02592-3","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T09:52:04Z","timestamp":1548323524000},"page":"622-626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5815-7471","authenticated-orcid":false,"given":"Jose D.","family":"Sandoval-Sus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Brahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ansari-Lari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,23]]},"reference":[{"key":"2592_CR1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","volume":"88","author":"RG Nador","year":"1996","unstructured":"Nador RG, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi\u2019s sarcoma-associated herpes virus. Blood. 1996;88:645\u201356.","journal-title":"Blood"},{"key":"2592_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Sherdlow","year":"2016","unstructured":"Sherdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"2592_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1097\/QAD.0000000000000428","volume":"28","author":"TM Gibson","year":"2014","unstructured":"Gibson TM, Morton LM, Shiels MS, Clarke CA, Engels EA. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28:2313\u20138.","journal-title":"AIDS"},{"key":"2592_CR4","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1200\/JCO.2004.11.097","volume":"22","author":"J Stebbing","year":"2004","unstructured":"Stebbing J, Gazzard B, Mandalia S, Teaque A, Waterston A, Marvin V, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2004;22:2177\u201383.","journal-title":"J Clin Oncol"},{"key":"2592_CR5","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","volume":"2","author":"C Simonelli","year":"2003","unstructured":"Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol. 2003;2:3948\u201354.","journal-title":"J Clin Oncol"},{"key":"2592_CR6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ajh.24251","volume":"91","author":"S Guillet","year":"2016","unstructured":"Guillet S, Gerard L, Meignin V, Agbalika F, Cuccini W, Denis B, et al. Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution. Am J Hematol. 2016;91:233\u20137.","journal-title":"Am J Hematol"},{"key":"2592_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4132\/KoreanJPathol.2014.48.2.81","volume":"48","author":"Y Kim","year":"2014","unstructured":"Kim Y, Park CJ, Roh J, Huh J. Current concepts in primary effusion lymphoma and other effusion-based lymphomas. Korean J Pathol. 2014;48:81\u201390.","journal-title":"Korean J Pathol"},{"key":"2592_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","volume":"12","author":"Y Chen","year":"2007","unstructured":"Chen Y, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007;12:569\u201376.","journal-title":"Oncologist"},{"issue":"11","key":"2592_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/01.pas.0000138177.10829.5c","volume":"28","author":"A Chadburn","year":"2004","unstructured":"Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28(11):1401\u201316.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2592_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1525-1578(10)60004-9","volume":"7","author":"A Carbone","year":"2005","unstructured":"Carbone A, Gloghini A, Vaccher E, Cerri M, Gaidano G, Dalla-Favera R, et al. Kapsoi\u2019s sarcoma-associated herpesvirus\/human herpesvirus type 8-positive solid lymphomas a tissue-based variant of primary effusion lymphoma. J Mol Diagn. 2005;7(1):17\u201327.","journal-title":"J Mol Diagn"},{"issue":"12","key":"2592_CR11","first-page":"4894","volume":"90","author":"G Gaidano","year":"1997","unstructured":"Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, et al. Association of Kaposi\u2019s sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138\/Syndecan-1 antigen. Blood. 1997;90(12):4894\u2013900.","journal-title":"Blood"},{"issue":"3","key":"2592_CR12","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/blood.V97.3.744","volume":"97","author":"A Carbone","year":"2001","unstructured":"Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, et al. Expression profile of MUM1\/IRF4, BCL-6, and CD138\/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97(3):744\u201351.","journal-title":"Blood"},{"issue":"19","key":"2592_CR13","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","volume":"23","author":"E Boulanger","year":"2005","unstructured":"Boulanger E, Gerard L, Gabarre J, Molina JM, Rapp C, Abino JF, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients With AIDS. J Clin Oncol. 2005;23(19):4372\u201380.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2592_CR14","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1080\/10428190600685467","volume":"47","author":"C Hoffmann","year":"2006","unstructured":"Hoffmann C, Wolf E, Wyen C, Fatkenheuer G, Van Luzen J, Stellbrink HJ, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006;47(9):1872\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2592_CR15","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/cncr.27918","volume":"119","author":"JM Ribera","year":"2013","unstructured":"Ribera JM, Garcia O, Grande C, Esteve J, Oriol A, Bergua J, et al. Dose-intensive chemotherapy including rituximab in Burkitt\u2019s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119(9):1660\u20138.","journal-title":"Cancer"},{"issue":"22","key":"2592_CR16","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(22):1029\u201341.","journal-title":"N Engl J Med"},{"issue":"7","key":"2592_CR17","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1182\/blood-2013-01-481713","volume":"122","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233\u201342.","journal-title":"Blood"},{"issue":"26","key":"2592_CR18","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798\u2013804.","journal-title":"Blood"},{"issue":"3","key":"2592_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1586\/14737140.2016.1146597","volume":"16","author":"KZ Oregel","year":"2016","unstructured":"Oregel KZ, Everett E, Zhang X, Nagaraj G. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. Expert Rev Anticancer Ther. 2016;16(3):279\u201383.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"2592_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/ccr3.1382","volume":"6","author":"JP Alderuccio","year":"2018","unstructured":"Alderuccio JP, Desai A, Yepes MM, Chapman JR, Vega F, Lossos IS. Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma. Clin Case Rep. 2018;6(4):634\u20137.","journal-title":"Clin Case Rep"},{"issue":"3","key":"2592_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<266::AID-AJH25>3.0.CO;2-7","volume":"57","author":"E Oksenhendler","year":"1998","unstructured":"Oksenhendler E, Clauvel JP, Jouveshomme S, Davi F, Mansour G. Complete remission of a primary effusion lymphoma with antiretroviral therapy. Am J Hematol. 1998;57(3):266.","journal-title":"Am J Hematol"},{"issue":"2","key":"2592_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00002030-200101260-00023","volume":"15","author":"L Hocqueloux","year":"2001","unstructured":"Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS. 2001;15(2):280\u20132.","journal-title":"AIDS"},{"issue":"1","key":"2592_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/cid\/ciu174","volume":"59","author":"HA Torres","year":"2014","unstructured":"Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. Clin Infect Dis. 2014;59(1):106\u201314.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2592_CR24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000001729","volume":"32","author":"PG Rubinstein","year":"2018","unstructured":"Rubinstein PG, Moore PC, Rudek MA, Henry DH, Ramos JC, et al. Brentuximab bedouin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. AIDS. 2018;32(5):605\u201311.","journal-title":"AIDS"},{"issue":"15","key":"2592_CR25","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","volume":"115","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximan plus concurrent infusions EPOCH chemotherapy is highly effective in HIV-associated B-Cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008\u201316. https:\/\/doi.org\/10.1182\/blood-2009-08-231613 .","journal-title":"Blood"},{"issue":"3","key":"2592_CR26","first-page":"83","volume":"102","author":"FB Sabattini","year":"2010","unstructured":"Sabattini FB, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83\u20137.","journal-title":"Pathologica"},{"issue":"4","key":"2592_CR27","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458\u201365.","journal-title":"Blood"},{"issue":"19","key":"2592_CR28","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"2592_CR29","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2592_CR30","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","volume":"131","author":"MA Fanale","year":"2018","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018;131(19):2120\u20134.","journal-title":"Blood"},{"issue":"4","key":"2592_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378(4):331\u201344.","journal-title":"N Engl J Med"},{"issue":"3","key":"2592_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ajh.10341","volume":"73","author":"E Boulanger","year":"2003","unstructured":"Boulanger E, Daniel MT, Agbalika F, Oksenhendler E. Combined chemotherapy including high-dose methotrexate in KSHV\/HHV8-associated primary effusion lymphoma. Am J Hematol. 2003;73(3):143\u20138.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02592-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02592-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02592-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T07:53:25Z","timestamp":1606118005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02592-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,23]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2592"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02592-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,23]]},"assertion":[{"value":"6 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}